moneycontrol.com network18online.com

 

SENSEX: 73651.35 655.04

NIFTY: 22326.90 203.25

Multi Baggers

PN Vijay

Investment Advisor

5.30 AM Jan 1st 1970

Alembic Pharma

BSE ID : 533573     NSE ID : APLLTD

RECOMMENDED PRICE 45.00

PEAK FROM RECO 1150.00 2,455.56%

CURRENT PRICE 982.35 Resource id #18

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharma company in India engaged in manufacture of fermentation and chemistry based bulk drugs.

Alembic Pharmaceuticals

Company Background

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharma company in India engaged in manufacture of fermentation and chemistry based bulk drugs.

The company is vertically integrated to develop, manufacture and market pharmaceutical products, pharmaceutical substances and intermediates. Alembic is the market leader in the macrolides segment of anti-infective drugs in India. The company’s manufacturing facilities are located at Panelav in Vadodara and Baddi in Himachal Pradesh. Its basket of formulations contain more than 150 products in several forms belonging to diverse therapeutic segments from anti-infective, cough & cold products to cardiovascular and oral anti-diabetics. The manufacturing expertise is available for almost all dosage forms including sterile as well as non sterile products.

Formulations which account for 65% of the total business today has manufacturing facility at three different places; namely Vadodara & Panelav at Gujarat in the west & Baddi at Himachal Pradesh in the north.The plant at Vadodara has the largest formulation capacity in India while the API and formulation manufacturing are undertaken at the Panelav facility. The company is also engaged in power generation through co-generation power plants and wind mills.

Key Financials:

Y/E March  FY10 FY11
Net Sales (Rs' Cr) 1199 1471
% chg 5.4 12.7
EBITDA 112 157
Margin (%) 10 12
Net Profit (Rs' Cr) 22 68
Margin (%) 1.9 5.6
EPS (Rs) 1.6 3.6
P/E (x) 25 11

Trading Data

CMP 45
Price Objective 65
Upside Potential 44%
Face Value Rs.2
Market Cap (Cr) 858
Free Float (Cr) 257
52 Week High/Date 51/20 Sept 11
52 Week Low/Date 34/ 2 Jan 12

Shareholding Pattern

Promoter 74.13
FII 7.2
DII 1.12
Others 17.55

Standalone Financial Results (Rs in Crores)

Particulars Q2FY12 Q3FY12 % QoQ 9MFY12
Net Sales 381 396 -3.6 1121
Other Income 1 - - 2
Total Income 382 396 - 1122
Gross Profit 192 202 -4.9 566
Gross margin (%) 50.3 51   50.5
Operating profit 68 60 11.9 179
Operating margin (%) 17.8 15.3   15.9
Interest 7 7 -1.4 21
Depreciation 8 8 -4.3 25
Profit before Tax 54 45 18.9 135
Taxation 9 7 33 24
Profit after Tax 44 38 16.3 111
EPS 2.3 2 - 5.9
Note- Yearly comparison is not possible as the company has started providing de-merged accounts from Q4FY11 onwards.

Key Q3FY12 highlights:

The company reported revenue growth of 15.5% yoy to Rs 381Cr mainly of back of exports, which grew by 50.4% yoy driven by the API and formulation business which grew by 113% yoy and 11% yoy respectively. However domestic formulation business reported slow growth at 7.9% yoy.

The company posted impressive performance across all its segments as contribution of the chronic segment forming around 35% of domestic formulation sales grew by 20% yoy and international generics to regulated markets grew by 13% yoy.

On the U.S. regulatory filing front, the company reported cumulative ANDA filings of 41 ANDAs in the U.S. with 17 approvals with two ANDA approvals during the quarter.

Operating profit for the quarter grew by 12% qoq on back of lower other expenditure. Other expenses as a percentage of sales reduced at 19.8% in Q3FY12 as compared to 23% in Q2FY12. Operating margin for the quarter stood strong at 15.3%.

Net profit for the quarter came in at Rs 44Cr, up by 16% qoq on back of higher revenue growth and expansions in operating margins.

Strengths

Expanded capacity and restructuring to drive top line

At present API contributes around 25% of overall revenues, however API segment is a low margin and commoditized segment and going forward the company is undertaking restructuring by shifting its focus from API to formulation segment with domestic formulation forming 57% of its total sales. The company has two formulation plants at Baddi and Panelav and is undertaking expansion plans at its Panelav facility by doubling its current capacity of 2.6bn tablets at the plant to 5bn tablets. The expanded facility is expected to be operational by Q3FY12 with potential increment sale from the capacity at Rs 350Cr.

Improvement in profitability and return ratios

On the operating front, the company’s operating margin is expected to improve from current 12% in FY11 to nearly 15% by FY13. Moreover the company looks forward to reduce its debt currently at 339Cr as it has no major capital expenditure except its planned capex.

Strong Product profile

Its brands such as Glycodin, Zeet, Sharkeferrol  are household names and command stable market share. Market has not given enough importance to this

Key Concerns

Export formulation business is contingent upon additional capacities and hence delay in commissioning of these facilities may lead to non achievement of export formulation orders.

Domestic API business declining to due higher competition from Chinese manufacturers.

Outlook & Valuation

Alembic Pharma Limited is a pure pharma play with strong foothold in domestic formulation business and increased focus in regulated markets. Post the restructuring, the company’s growth and profitability profile has improved. Revenues from the international market serve as the next big trigger for the company. Revenues and net profits are expected to post 16% and 30% CAGR over FY11-13. Given the strong secondary numbers posted by the company and better hygiene factors in the domestic space, the company is set on a sustainable growth path. At the CMP of 45, the stock is trading at 6.5/5.3x its FY12/13 EPS  of 6.9 and 8.5 respectively. Hence a BUY rating is recommended with a price target of 65, an upside of nearly 44% in the next 12-15 months time horizon.

Super Combo
  3200

Powerful mix of technical and commodity packs with timely expert.

Technical
2000

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Commodities
2000

Stay on top of the Indian Commodities Market with commodity trading calls Intraday, and Positional (Short & Long-Term Calls).

Log on to

http://m.poweryourtrade.com

on your phone and stay updated on the go!

ISO 27001 - BSI Assurance Mark